SANGAMO THERAPEUTICS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
SANGAMO THERAPEUTICS INC. - More news...
SANGAMO THERAPEUTICS INC. - More news...
- Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
- Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
- Sangamo Announces Closing of Biogen Collaboration Agreement
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
- Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
- Sangamo Therapeutics Appoints John Markels to Its Board of Directors
- Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
- Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
- Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
- Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
- Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
- Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
- Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
- Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
-
Sangamo Therapeutics, Inc. - SGMO Stock Chart Technical Analysis for 07-08-2019
- Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
- Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
- Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
- Sangamo Therapeutics Reports First Quarter 2019 Financial Results
- Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
- Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
- Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
- Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
- Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
-
Sangamo Therapeutics, Inc. - SGMO Stock Chart Technical Analysis for 04-02-2019
- Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
- Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
